Megan Garlapow, PhD

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.

All articles by Megan Garlapow, PhD

Micro-dystrophin gene therapy improves survival but may pose long-term risks

Micro-dystrophin gene therapy greatly extended lifespan and improved heart function in severe DMD preclinical models.
PBGENE-DMD receives Rare Pediatric Disease Designation from FDA

PBGENE-DMD could help up to 60% of patients with Duchenne muscular dystrophy by permanently editing their dystrophin gene.
New gene therapy delivery approach restores full-length dystrophin in DMD mice

A new gene therapy using triple AAV vectors restored full-length dystrophin and improved muscle function in mice with DMD.
Prenatal stress shapes future health in mouse model of DMD

Stress during late pregnancy changed how Duchenne muscular dystrophy (DMD) impacted offspring in a mouse model.
Gene therapy Elevidys expands hope for patients with Duchenne

Elevidys is a one-time gene therapy that helps patients with DMD produce a key muscle protein and is under ongoing safety evaluation.
CRISPR gene editing offers new hope for treating Duchenne

CRISPR shows promise in correcting DMD mutations and restoring dystrophin, and future patients may benefit from personalized strategies.
Review identifies what physical activity really means to people with DMD

For people with DMD, physical activity is about more than walking, with independence and quality of life tied to meaningful movement.
How muscle strength and flexibility shift over time in boys with DMD

Muscle weakness in Duchenne muscular dystrophy (DMD) does not follow a simple decline, but has periods of stability before worsening.
Novel gene variants shed light on muscular dystrophy diagnosis

Researchers identified two previously unreported mutations in the Dystrophin gene, providing new insights into muscular dystrophy.
Study identified differences in DMD treatment across ethnicities

Patients of different racial and ethnic backgrounds with DMD received different treatments and had varying health care costs.

Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

The DMD Journey